1. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion
   Qiang Yin et al, 2022, Thoracic Cancer CrossRef
2. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
   Giuseppe Lo Russo et al, 2017, Oncotarget CrossRef
3. Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
   Huiyan Deng et al, 2019, Pathology - Research and Practice CrossRef
4. Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis
   Yang Shao et al, 2017, BioMed Research International CrossRef
5. Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report
   Wenhua Liang et al, 2016, BMC Cancer CrossRef
6. Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
   Haoyue Hu et al, 2023, Frontiers in Pharmacology CrossRef
7. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
   Hongbiao Wang et al, 2022, Medicine CrossRef
8. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
   Chun-wei Xu et al, 2018, Journal of Translational Medicine CrossRef
9. Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
   Sabine Schmid et al, 2017, Journal of Thoracic Oncology CrossRef